Joyce Wald, DO
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1275522120
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abiomed at 31.1% of the total.
Across 423 payments — averaging $229.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$30K
- Impulse Dynamics (USA) Inc.$24K
- Abbott$22K
- Boston Scientific$13K
- Medtronic$6K
- Cvrx, Inc.$746
- plus $2K from 11 others
Across 13 payments — averaging $12,937 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$118K
- Impulse Dynamics (USA) Inc.$45K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Consulting fees$28,42029%
- Speaking & faculty fees$38,48840%
- Travel & lodging$11,44512%
- Food & beverage$18,54919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 92 | $30,100 |
| Impulse Dynamics (USA) Inc. | 63 | $24,292 |
| Abbott | 140 | $21,686 |
| Boston Scientific | 21 | $12,788 |
| Medtronic(2 entities) | 28 | $5,769 |
| Cvrx, Inc. | 14 | $746 |
| Kestra Medical Technology Services, Inc. | 14 | $457 |
| Novartis | 36 | $421 |
| Daxor Corporation | 1 | $128 |
| Paragonix Technologies, Inc. | 1 | $121 |
| Merck | 2 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $76 |
| AstraZeneca | 1 | $70 |
| Amgen | 3 | $68 |
| Philips North America LLC | 1 | $33 |
| Novo Nordisk | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$45,557
- Impella$21,726
- MitraClip$7,954
- GENERAL - STRUCTURAL HEART$5,000
- CentriMag$4,923
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,604
- CardioMEMS HF System$1,920
- GENERAL - THERAPIES$931
- HeartWare HVAD$558
- Barostim Neo System$287
- HeartMate$269
- HeartMate 3 Left Ventricular Dev$250
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$168
- WATCHMAN FLX$135
- BVA-100$128
- HeartMate 3 Left Ventricular Assist Device$125
- SherpaPak$121
- GENERAL CATHETER$116
How this compares
$96,902 in reported general payments places this provider in the 85th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 361 | $480,854 |
| FarxigaDapagliflozin Propanediol | 130 | $135,356 |
| JardianceEmpagliflozin | 75 | $90,024 |
| EliquisApixaban | 29 | $39,823 |
| Sildenafil Citrate | 57 | $34,514 |
| VascepaIcosapent Ethyl | 13 | $7,927 |
| Metoprolol Succinate | 409 | $7,038 |
| Bumetanide | 78 | $5,593 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,546 |
| Carvedilol | 357 | $4,646 |
| Valsartan | 89 | $3,812 |
| Potassium Chloride | 85 | $3,478 |
| Rosuvastatin Calcium | 149 | $3,002 |
| Atorvastatin Calcium | 232 | $2,981 |
| Torsemide | 82 | $2,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $421 | $480,854361 claims |
| AstraZenecaFarxiga | $70 | $135,356130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
- Nosheen RezaPhiladelphia$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.